More pivotal COPD data for Almirall/Forest support filings
This article was originally published in Scrip
Executive Summary
Almirall and Forest Laboratories have released top-line results from a second pivotal Phase III trial of its LAMA/LABA combination treatment for COPD, which failed to hit one of its co-primary endpoints.